Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 16/20 | 0.84 |
| ▸ | MMP13 | P45452 | 9/20 | 0.84 |
| ▸ | MMP2 | P08253 | 4/20 | 0.84 |
| ▸ | MMP9 | P14780 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794928 | 0.91 | ADAM17 (1.00) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6795271 | 0.91 | ADAM17 (1.00) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6788849 | 0.90 | ADAM17 (1.00) | ADAM17MMP13MMP2MMP9 | |
| Trifluoroacetic Acid SCHEMBL6787337 | 0.87 | ADAM17 (0.91) | ADAM17MMP13MMP2MMP9 | |
| Trifluoroacetic Acid SCHEMBL6794294 | 0.86 | ADAM17 (0.91) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6787341 | 0.85 | ADAM17 (0.77) | ADAM17MMP13MMP2MMP9 | |
| Trifluoroacetic Acid SCHEMBL6790603 | 0.85 | ADAM17 (0.91) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6794297 | 0.85 | ADAM17 (0.78) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6790608 | 0.84 | ADAM17 (0.77) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6794665 | 0.84 | ADAM17 (1.00) | ADAM17MMP13MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074810-B2 | Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-11 | — | — | US | disclosed |
| US-20040116491-A1 | Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-17 | — | — | US | disclosed |